Home » Stocks » Assembly Biosciences

Assembly Biosciences, Inc. (ASMB)

Stock Price: $15.35 USD -0.20 (-1.29%)
Updated Oct 20, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 504.32M
Revenue (ttm) 52.45M
Net Income (ttm) -71.46M
Shares Out 32.85M
EPS (ttm) -2.31
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 20, 2020
Last Price $15.35
Previous Close $15.55
Change ($) -0.20
Change (%) -1.29%
Day's Open 15.55
Day's Range 14.62 - 16.22
Day's Volume 308,960
52-Week Range 10.23 - 27.84

More Stats

Market Cap 504.32M
Enterprise Value 288.74M
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 32.85M
Float 30.63M
EPS (basic) -2.49
EPS (diluted) -2.31
FCF / Share -2.49
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.85M
Short Ratio 13.09
Short % of Float 12.58%
Beta 1.20
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 9.61
PB Ratio 1.90
Revenue 52.45M
Operating Income -75.79M
Net Income -71.46M
Free Cash Flow -87.94M
Net Cash 215.58M
Net Cash / Share 6.56
Gross Margin -133.06%
Operating Margin -144.49%
Profit Margin -136.20%
FCF Margin -167.66%
ROA -17.27%
ROE -32.35%
ROIC -38.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (6)

Buy 5
Overweight 1
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$45.40*
(195.77% upside)
Low
30.0
Current: $15.35
High
74.0
Target: 45.40
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue15.9614.809.02-------
Revenue Growth7.83%64.14%--------
Gross Profit15.9614.809.02-------
Operating Income-103-92.74-52.23-45.28-29.66-23.96-19.60-24.86-34.00-4.77
Net Income-97.63-90.75-42.81-44.26-28.45-23.79-19.40-24.79-34.34-15.29
Shares Outstanding26.2622.8017.7517.2315.707.003.882.551.920.12
Earnings Per Share-3.72-3.98-2.41-2.57-1.81-3.40-5.00-9.70-17.85-123.35
Operating Cash Flow-84.07-64.961.86-34.88-18.70-14.97-17.80-21.38-25.07-5.21
Capital Expenditures-1.55-0.34-0.87-0.15-0.06-0.15-0.01--0.01-
Free Cash Flow-85.62-65.301.00-35.03-18.76-15.12-17.80-21.38-25.08-5.21
Cash & Equivalents27421812052.9667.6629.0927.0620.4936.9814.57
Total Debt12.27--------2.49
Net Cash / Debt26221812052.9667.6629.0927.0620.4936.9812.08
Assets34026816998.1213471.2327.1320.5637.0514.62
Liabilities66.6957.3956.1818.2415.0012.652.642.752.512.99
Book Value27321111379.8811958.5724.4917.8134.5311.63
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Assembly Biosciences, Inc.
Country United States
Employees 139
CEO John G. McHutchison

Stock Information

Ticker Symbol ASMB
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ASMB
IPO Date December 17, 2010

Description

Assembly Biosciences operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome. It is involved in the development of core inhibitors that inhibit the functional activities of HBV core protein at various points in the viral lifecycle. The company's microbiome program consists of an integrated platform that includes the disease-targeted strain isolation, identification, characterization, and selection process for strain purification and growth under current good manufacturing practice conditions; and a licensed patented delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. Its product candidates include ABI-H0731 that is in Phase 2a clinical trials for the treatment of HBV; ABI-H2158, which is in Phase 1a/1b dose-ranging clinical study in the HBV-cure program; and ABI-H3733 that is in preclinical studies for the treatment of HBV. In addition, the company engages in the development of product candidates for various disease indications, such as Crohn's disease, irritable bowel syndrome, immune-mediated and metabolic disorders, and oncology by using its microbiome platform. It has a collaboration agreement with Allergan Pharmaceuticals International Limited for the development and commercialization of various microbiome gastrointestinal programs. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in South San Francisco, California.